Related Experiment Video
Updated: May 28, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability
Emilia Orzechowska1, Ewa Kozłowska, Krzysztof Staroń
1Institute of Biochemistry, Faculty of Biology, University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland.
Abstract:
Inhibitors of CK2 kinase inhibit cell proliferation and induce apoptosis in numerous cancer cell lines. Due to these properties, they are considered potentially useful in anticancer therapy. In this study, we show that the exact effect of the specific CK2 inhibitor TBB on PC-3 human prostate cancer cell viability depends on the time schedule of administration: it was not observed when the treatment was directly followed by the viability assay but it appeared when the treatment and the assay were separated by a 24-h incubation without the inhibitor. Such a pattern was maintained when the TBB treatment was combined with either camptothecin or TRAIL. The time schedule-dependence of cell viability was not reflected by a similar dependence of induction of apoptosis. Despite this, the schedule in which a treatment with the CK2 inhibitor precedes that with an anticancer drug seems to be a good choice for a potential therapy against androgen-refractory prostate cancer.
Insights
The timing of CK2 kinase inhibitor (TBB) administration affects prostate cancer cell viability. Preceding anticancer drug treatment with TBB shows promise for androgen-refractory prostate cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- CK2 kinase inhibitors show potential in cancer therapy by inhibiting cell proliferation and inducing apoptosis.
- Prostate cancer, particularly androgen-refractory forms, remains a significant therapeutic challenge.
Purpose of the Study:
- To investigate the impact of the specific CK2 inhibitor TBB on PC-3 human prostate cancer cell viability.
- To determine if the administration schedule of TBB influences its effect on cancer cell viability, alone or in combination with other agents.
Main Methods:
- Treatment of PC-3 prostate cancer cells with the CK2 inhibitor TBB.
- Varying the time interval between TBB treatment and viability assays.
- Combination treatments with camptothecin or TRAIL.
- Assessment of apoptosis induction.
Main Results:
- The effect of TBB on cell viability was schedule-dependent, appearing only after a 24-h incubation period post-treatment.
- This schedule-dependence was observed when TBB was used alone or combined with camptothecin or TRAIL.
- Apoptosis induction by TBB did not exhibit the same schedule-dependence as cell viability.
Conclusions:
- The administration sequence of CK2 inhibitors is crucial for their efficacy in prostate cancer treatment.
- A therapeutic strategy involving CK2 inhibition preceding treatment with other anticancer drugs may be effective against androgen-refractory prostate cancer.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
